This study will continue to evaluate the performance of the MarrowStim™ PAD Kit to treat subjects with critical limb ischemia (CLI) caused by severe PAD.
This is a continued access enrollment intended for subjects with critical limb ischemia (CLI) that are unsuitable for revascularization. The investigational treatment utilizes autologous concentrated bone marrow aspirate (cBMA) at the point of care. The bone marrow aspirate is obtained from the subject's hip, concentrated with a bone marrow concentration device, and delivered intramuscularly to the affected limb. Subjects meeting the inclusion/exclusion criteria will be treated with the MarrowStim™ PAD Kit and followed for a total of five years. Information on subject outcomes, such as the occurrence of amputation and death, as well as measurements of rest pain, blood flow (ankle-brachial index, toe-brachial index), and quality of life will be collected. Safety information (via adverse event reporting) will also be collected.
Study Type
EXPANDED_ACCESS
Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
Central Arkansas Veterans Healthcare System
Little Rock, Arkansas, United States
Piedmont Hospital
Atlanta, Georgia, United States
Indiana University
Indianapolis, Indiana, United States
Tufts Medical Center
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boston, Massachusetts, United States
Holy Name Medical Center
Teaneck, New Jersey, United States
The Mount Sinai Hospital
New York, New York, United States
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York, United States
Cleveland Clinic
Cleveland, Ohio, United States
VA Pittsburgh Healthcare System
Pittsburgh, Pennsylvania, United States